You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海王生物(000078.SZ):海王醫藥研究院的HW130注射液完成I期臨牀試驗

格隆匯7月3日丨海王生物(000078.SZ)公佈,公司全資子公司深圳海王醫藥科技研究院有限公司(簡稱“海王醫藥研究院”)研發的HW130注射液已於近日完成I期臨牀試驗,並取得I期臨牀研究報告。

HW130注射液是海王醫藥研究院自主研發、具有自主知識產權的新型抗腫瘤藥物,分別獲得國家藥品監督管理局、美國FDA臨牀試驗許可。具有腫瘤血管阻斷作用以及降低腫瘤化療治療嚴重不良反應和化療增敏作用,提升腫瘤綜合治療的臨牀效益;對正常器官組織的損傷輕微,具有高度的靶向性。該項目的開發,可一定程度上解決臨牀未被滿足的臨牀需求,具有較大的開發潛力與市場空間。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account